# Tailoring Obesity Treatment Trial

> **NCT06619015** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Esbjerg Hospital - University Hospital of Southern Denmark**

## Conditions studied

- Obesity
- Appetite Regulation
- PreDiabetes

## Interventions

- **DRUG:** Pramlintide Acetate 1 MG/ML
- **DRUG:** Semaglutide Pen Injector
- **DRUG:** Sodium Chloride 0.9% Inj

## Key facts

- **NCT ID:** NCT06619015
- **Lead sponsor:** Esbjerg Hospital - University Hospital of Southern Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-04-01
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-04-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** suspended by the danish medical agency
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06619015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06619015, "Tailoring Obesity Treatment Trial". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06619015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*